Latest Breaking News On - Diagnostic cortex - Page 1 : comparemela.com

Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement

Biodesix, Inc. , a leading diagnostic solutions company with a focus in lung disease, today announced the pricing of its underwritten offering of 17,391,832 shares of its common stock at a price to.

United statesRiverside plazaNew yorkCanaccord genuityWilliam blairSyndicate departmentWilliam blair companyTd securities united statesOffice squareExchange commissionBiodesix incProspectus departmentNon voting convertible preferred stockStreet capital marketsSecurities actOne post office square

Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center

Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Scott huttonSimon mayGary pestano biodesixBiodesix incUs cancer centerMemorial sloan kettering cancer centerBiodesix announces new master collaborative research agreementLife sciences at bio rad laboratoriesInternational precision medicine triProduct serviceHoward scherGary pestanoInternational precision medicine tri conAcademic collaboration framework focusedNovel diagnostic test developmentLife sciences

Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights

Persistent, high double-digit growth in Lung Diagnostic test volume - growing 65% in FY2023 versus FY2022 - and the sixth consecutive quarter with greater than 50% year-over-year growth; Ongoing.

United statesScott huttonBiopharma servicesBiodesix incBiopharmaceutical servicesLung diagnosticFull yearNodify lungNodule risk assessmentPerceptive advisorsInvestors pageDiagnostic cortexArtificial intelligencePrivate securities litigation reform actRisk factorsBalance sheets

Biodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024

Biodesix, Inc. , a leading diagnostic solutions company with a focus in lung disease, announced today that it will release financial results for the fourth quarter and year ended December 31, 2023.

Biodesix incNodify lungDiagnostic cortexArtificial intelligencePrivate securities litigation reform actRisk factors

Biodesix (BDSX) Reports Publication of the ORACLE Clinical Utility Study

Biodesix (BDSX) Reports Publication of the ORACLE Clinical Utility Study
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Robbie luntChris brinzeyScott huttonBiodesix incNodify lungDiagnostic cortexArtificial intelligencePrivate securities litigation reform actRisk factors